BioSpace News Archive

New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network adds important knowledge about how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.

Charles River Laboratories International, Inc. announced that it will virtually present at three upcoming investor conferences, including

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced the publication of medical technologies guidance for the Axonics r-SNM System by the National Institute for Health and Care Excellence (NICE).

9 Meters Biopharma, Inc., announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast.

ValGenesis, Inc., a market leader in paperless validation solutions, announced that its Validation Lifecycle Management System supports Augmented Reality for remote and hands-free validation, to improve efficiency, data integrity, and compliance in the corporate validation process.

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that 3 additional patients have completed the 48-week Phase I/II study.

Progression to Phase 3 clinical trials represents significant acceleration of atopic dermatitis development program Previously reported data demonstrated evidence that roflumilast cream provided symptomatic improvement and a favorable tolerability profile Roflumilast cream is a novel PDE4 inhibitor being developed as a once-daily topical cream for atopic dermatitis and psoriasis WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2), (the “Company” or “EXM”), an emerging bio-sciences company specializing in the production of unique cannabinoid formulations, is pleased to announce its success in securing COVID-19 R&D-focused grant from the European Union and the Portuguese Government, detailing a landmark event for the Company.

Orbis International announces the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over four years.

Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer,